Insmed's Options: A Look at What the Big Money Is Thinking
Insmed's Options: A Look at What the Big Money Is Thinking
In today's trading context, the average open interest for options of Insmed stands at 2968.25, with a total volume reaching 15,604.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Insmed, situated within the strike price corridor from $62.5 to $85.0, throughout the last 30 days.Financial giants have made a conspicuous bearish move on Insmed. Our analysis of options history for Insmed (NASDAQ:INSM) revealed 13 unusual trades.
金融巨頭對Insmed採取了明顯的看淡舉動。我們對Insmed（納斯達克:INSM）期權歷史的分析顯示出13筆飛凡交易。
Delving into the details, we found 7% of traders were bullish, while 76% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $855,036, and 3 were calls, valued at $419,310.
深入細節後，我們發現7%的交易者持看漲看法，而76%顯示看淡傾向。在我們發現的所有交易中，有10筆看跌期權，價值855,036美元，而有3筆看漲期權，價值419,310美元。
Expected Price Movements
預期價格波動
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $62.5 to $85.0 for Insmed over the recent three months.
根據交易活動情況，顯然重要投資者的目標價位區間爲62.5美元至85.0美元，持續近三個月的時間。
Analyzing Volume & Open Interest
分析成交量和未平倉合約
In today's trading context, the average open interest for options of Insmed stands at 2968.25, with a total volume reaching 15,604.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Insmed, situated within the strike price corridor from $62.5 to $85.0, throughout the last 30 days.
在今日的交易情境中，Insmed期權平均持倉量爲2968.25，總成交量達到15,604.00。伴隨的圖表描繪了Insmed的高價值交易在過去30天內從62.5美元至85.0美元的行使價走廊中的看漲和看跌期權成交量和持倉量的發展。
Insmed Option Volume And Open Interest Over Last 30 Days
過去30天內Insmed期權成交量和持倉量
Biggest Options Spotted:
最大的期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| INSM | CALL | TRADE | BULLISH | 01/17/25 | $1.2 | $0.75 | $1.2 | $85.00 | $360.0K | 7.1K | 3.0K |
| INSM | PUT | SWEEP | BEARISH | 01/17/25 | $4.1 | $3.8 | $4.06 | $62.50 | $150.3K | 504 | 2.3K |
| INSM | PUT | SWEEP | BEARISH | 01/17/25 | $4.5 | $3.4 | $3.9 | $62.50 | $142.3K | 504 | 365 |
| INSM | PUT | SWEEP | BEARISH | 01/17/25 | $4.0 | $3.7 | $4.0 | $62.50 | $138.4K | 504 | 1.5K |
| INSM | PUT | SWEEP | BEARISH | 01/17/25 | $4.0 | $3.7 | $4.0 | $62.50 | $123.2K | 504 | 746 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| insm公司 | 看漲 | 交易 | BULLISH | 01/17/25 | $1.2 | $0.75 | $1.2 | $85.00 | 360,000美元 | 7.1千 | 3.0K |
| insm公司 | 看跌 | SWEEP | 看淡 | 01/17/25 | $4.1 | $3.8 | $4.06 | $62.50 | $150.3K | 504 | 2.3K |
| insm公司 | 看跌 | SWEEP | 看淡 | 01/17/25 | $4.5 | $3.4 | $3.9 | $62.50 | $142.3K | 504 | 365 |
| insm公司 | 看跌 | SWEEP | 看淡 | 01/17/25 | $4.0 | $3.7 | $4.0 | $62.50 | $138.4K | 504 | 1.5千 |
| insm公司 | 看跌 | SWEEP | 看淡 | 01/17/25 | $4.0 | $3.7 | $4.0 | $62.50 | $123.2K | 504 | 746 |
About Insmed
關於Insmed
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Insmed是一家全球生物製藥公司，正在改變患有嚴重罕見病的患者的生活。該公司的首個商業產品是ARIKAYCE（阿米卡星脂質體吸入懸濁液），已在美國獲批用於治療分枝桿菌複合體（MAC）肺部疾病，作爲成人患者治療方案中的一部分，針對無法或有限的另類治療選擇。該公司較早階段的臨床管線包括Brensocatib，這是一種新型口服可逆二肽基肽酶1抑制劑，在非囊性纖維化支氣管擴張症和其他炎症性疾病中具有治療潛力；以及INS1009，一種曲前列素前藥的吸入製劑，可能爲肺動脈高壓提供不同的產品特點。
After a thorough review of the options trading surrounding Insmed, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
經過對圍繞Insmed的期權交易進行徹底審查後，我們繼續對該公司進行更詳細的審查。這包括評估其當前市場地位和表現。
Where Is Insmed Standing Right Now?
Insmed目前處於什麼位置？
- With a trading volume of 891,951, the price of INSM is down by -0.03%, reaching $66.27.
- Current RSI values indicate that the stock is may be approaching oversold.
- Next earnings report is scheduled for 94 days from now.
- 交易量爲891,951股，INSm的價格下跌了-0.03%，達到66.27美元。
- 當前RSI值表明該股票可能即將超賣。
- 下一個盈利報告將在94天后發佈。
Professional Analyst Ratings for Insmed
Insmed的專業分析師評級
2 market experts have recently issued ratings for this stock, with a consensus target price of $97.5.
最近有2位市場專家爲這隻股票發表了評級意見，共識目標價爲97.5美元。
Unusual Options Activity Detected: Smart Money on the Move
檢測到期權異動：智慧資金在行動。
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.* In a cautious move, an analyst from Truist Securities downgraded its rating to Buy, setting a price target of $105. * Reflecting concerns, an analyst from HC Wainwright & Co. lowers its rating to Buy with a new price target of $90.
Benzinga Edge的期權異動板塊可以提前發現潛在的市場變動。查看大宗交易資金正在投資的您最喜愛股票的頭寸。單擊此處查看更多信息。*作爲謹慎舉措，Truist Securities的分析師將評級調降至買入，並設定目標價爲105美元。* 紋反映擔憂，HC Wainwright & Co.的分析師將買入評級下調，並設定新目標價爲90美元。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Insmed options trades with real-time alerts from Benzinga Pro.
期權交易存在更高的風險和回報機會。精明的交易員通過不斷學習、調整策略、監控多個因子以及密切關注市場波動來管理這些風險。從Benzinga Pro實時警報中了解最新的Insmed期權交易情況。
譯文內容由第三人軟體翻譯。
